耳鼻喉科Pubmed文献追踪每日 14:00 同步
← 返回全部文献
Article record

HPV阳性鼻窦及鼻咽癌患者循环肿瘤HPV-DNA的检测

Detection of circulating tumor HPV-DNA in patients with HPV-positive sinonasal and nasopharyngeal carcinoma.

临床研究鼻咽癌IF 2.8Q3

文献信息

PMID42898009
原文在 PubMed 查看原文 ↗
发表日期2026
作者Jakob Myllerup Jensen
查看其他 6 位作者

Simone Kloch Bendtsen；Kathrine Kronberg Jakobsen；Katalin Kiss；Maria Rossing；Christian Grønhøj；Christian Von Buchwald

作者单位Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Copenhagen University Hospital - Rigshospitalet, Denmark.
查看其他 2 条单位信息

Department of Pathology, Copenhagen University Hospital - Rigshospitalet, Denmark.；MDxCORE, Department of Clinical Biochemistry, Copenhagen University Hospital - Rigshospitalet, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen.

期刊Acta oncologica (Stockholm, Sweden)
SCI 分区Q3
IF2.8
研究类型临床研究 · 临床
所属专科鼻咽癌

中文摘要

背景： 约30%的鼻窦及鼻咽癌病例与HPV相关，然而针对这些患者循环肿瘤HPV-DNA（ctHPV-DNA）的研究十分匮乏。本研究旨在探讨HPV阳性（HPV+）鼻窦及鼻咽癌患者治疗前血液样本中ctHPV-DNA的敏感性。
方法： 纳入2017—2025年期间在丹麦哥本哈根Rigshospitalet耳鼻咽喉头颈外科与听力学部接受治疗的经确诊HPV+鼻窦或鼻咽癌患者。于治疗开始前使用Streck管采集血样，并通过微滴式数字PCR（ddPCR）分析ctHPV-DNA的存在。
结果： 共纳入15例原发性HPV+鼻窦或鼻咽癌患者。除2例HPV相关多表型癌外，其余均为鳞状细胞癌。HPV16最为常见，见于6例患者（40%）。此外还检出HPV18（n=2）、HPV33（n=1）、HPV35（n=3）、HPV45（n=1）和HPV56（n=2）。在纳入患者治疗前血样中检测ctHPV-DNA的敏感性为80%。ctHPV-DNA水平随T分期升高而显著增加。
结论： 在80%的HPV+鼻窦及鼻咽癌患者治疗前血样中检测到ctHPV-DNA。这支持进一步研究ctHPV-DNA作为这些患者治疗后监测生物标志物的价值。

英文摘要

BACKGROUND: Approximately 30% of sinonasal and nasopharyngeal carcinoma cases are HPV-associated, yet studies investigating circulating tumor HPV-DNA (ctHPV-DNA) among these patients are scarce. The aim of this study was to investigate the sensitivity of ctHPV-DNA in pretreatment blood samples from patients with HPV-positive (HPV+) sinonasal and nasopharyngeal carcinoma.
METHODS: Patients with a confirmed HPV+ sinonasal or nasopharyngeal carcinoma treated at the Department of Otorhinolaryngology, Head and Neck Surgery and Audiology at Rigshospitalet, Copenhagen, Denmark in the period 2017-2025 were included in this study. Blood samples were drawn in Streck tubes before treatment initiation and analysed for the presence of ctHPV-DNA by Droplet digital PCR (ddPCR).
RESULTS: Fifteen patients with primary HPV+ sinonasal or nasopharyngeal carcinoma were included. Except for two cases of HPV-related multiphenotypic carcinoma, all cases were squamous cell carcinoma. HPV16 was most prevalent and found in 6 patients (40%). HPV18 (n = 2), HPV33 (n = 1), HPV35 (n = 3), HPV45 (n = 1), and HPV56 (n = 2) were also represented. The sensitivity of detecting ctHPV-DNA in the pretreatment blood samples of the included patients was 80%. The level of ctHPV-DNA increased significantly with increasing T-category.
CONCLUSION: ctHPV-DNA was detected in pretreatment blood samples in 80% of patients with HPV+ sinonasal and nasopharyngeal carcinoma. This supports further investigation of ctHPV-DNA as a biomarker for post-treatment surveillance in these patients.